Elizabeth Holmes
Elizabeth Anne Holmes is an American biotechnology entrepreneur who was convicted of fraud in connection with her blood-testing company, Theranos. The company's valuation soared after it claimed to have revolutionized blood testing by developing methods that needed only very small volumes of blood, such as from a fingerprick. In 2015, Forbes had named Holmes the youngest and wealthiest self-made female billionaire in the United States on the basis of a $9-billion valuation of her company. In the following year, as accusations of fraud about Theranos's claims began to surface, Forbes revised its estimate of Holmes's net worth to zero, and Fortune named her in its feature article on "The World's 19 Most Disappointing Leaders".
The decline of Theranos began in 2015, when a series of journalistic and regulatory investigations revealed doubts about the company's claims and whether Holmes had been truthful with investors and the government. In 2018, the U.S. Securities and Exchange Commission charged Theranos, Holmes, and former Theranos chief operating officer Ramesh "Sunny" Balwani with raising $700 million from investors through a fraud involving false or exaggerated claims about the accuracy of the company's blood-testing technology; Holmes settled the charges by paying a $500,000 no admit no deny fine, returning 18.9 million shares to the company, relinquishing her voting control of Theranos, and accepting a ten-year ban from serving as an officer or director of a public company.
Holmes was in a clandestine romantic relationship with Balwani throughout most of Theranos's history. Holmes and Balwani jointly ran the company with a "dysfunctional corporate culture" of "secrecy and fear" according to employees. Staff also claimed that those who "raised concerns or objections" were "usually marginalized or fired" by the pair. Following the collapse of Theranos, Holmes started dating hotel heir William "Billy" Evans, whom she married in 2019 and with whom she has had two children.
In June 2018, a federal grand jury indicted Holmes and Balwani on fraud charges. Her trial in the case of U.S. v. Holmes, et al. ended in January 2022 when Holmes was convicted of defrauding investors and acquitted of defrauding patients. She was sentenced to serve years at Federal Prison Camp, Bryan, beginning on May 30, 2023. She and Balwani were ordered to pay $452 million in restitution to the victims of the fraud. The credibility of Theranos was attributed in part to Holmes's personal connections and ability to recruit the support of influential people, including Henry Kissinger, George Shultz, James Mattis, and Betsy DeVos, all of whom had served or would go on to serve as U.S. presidential cabinet officials.
Early life
Elizabeth Anne Holmes was born on February 3, 1984, in Washington, D.C. Her father, Christian Rasmus Holmes IV, was a vice president at a subsidiary of Enron called Clean Energy Solutions Group. Her mother, Noel Anne, worked as a Congressional committee staffer. Christian later held executive positions in government agencies such as USAID, the EPA, and USTDA. Holmes is partly of Danish ancestry. One of her paternal great-great-great-grandfathers was Charles Louis Fleischmann, a Jewish-Hungarian immigrant to the United States who founded Fleischmann's Yeast. The Holmes family "was very proud of its yeast empire" history, according to a family friend Joseph Fuisz, "I think the parents very much yearned for the days of yore when the family was one of the richest in America. And I think Elizabeth channeled that, and at a young age."Holmes graduated from high school at St. John's School in Houston. During high school, she was interested in computer programming and says she started her first business selling C++ compilers to Chinese universities. Her parents had arranged Mandarin Chinese home tutoring, and partway through high school, Holmes began attending Stanford University's summer Mandarin program. In 2002, Holmes attended Stanford, where she studied chemical engineering and worked as a student researcher and laboratory assistant in the School of Engineering. She was a member of Kappa Alpha Theta at Stanford.
After the end of her freshman year, Holmes worked in a laboratory at the Genome Institute of Singapore and tested for severe acute respiratory syndrome coronavirus through the collection of blood samples with syringes. She filed her first patent application on a wearable drug-delivery patch in 2003. Holmes reported that she was raped at Stanford in 2003. In March 2004, she dropped out of Stanford's School of Engineering and used her tuition money as seed funding for a consumer healthcare technology company.
Theranos
Founding
In 2003, Holmes founded the company Real-Time Cures in Palo Alto, California, to "democratize healthcare". Holmes described her fear of needles as a motivation and sought to perform blood tests using only small amounts of blood. When Holmes pitched the idea to reap "vast amounts of data from a few droplets of blood derived from the tip of a finger" to a medicine professor Phyllis Gardner at Stanford, who responded, "I don't think your idea is going to work", explaining it was impossible to do what Holmes was claiming could be done. Several other expert medical professors told Holmes the same thing.. However, Holmes did not relent, and she succeeded in getting her advisor and dean at the School of Engineering, Channing Robertson, to back her idea. In 2003, Holmes renamed the company Theranos. The company's original name was changed after deciding that too many people were skeptical of the word "cure". Robertson became the company's first board member and introduced Holmes to venture capitalists.Funding and expansion
By December 2004, Holmes had raised $6 million to fund the firm. By the end of 2010, Theranos had more than $92 million in venture capital. In July 2011, Holmes was introduced to former secretary of state George Shultz. After a two-hour meeting, he joined the Theranos board of directors. Holmes was recognized for forming "the most illustrious board in U.S. corporate history" over the next three years.Holmes operated Theranos in "stealth mode" without press releases or a company website until September 2013, when the company announced a partnership with Walgreens to launch in-store blood sample collection centers. She was interviewed for Medscape by its editor-in-chief, Eric Topol, who praised her for "this phenomenal rebooting of laboratory medicine". Media attention increased in 2014, when Holmes appeared on the covers of Fortune, Forbes, T: The New York Times Style Magazine, and Inc.
Forbes recognized Holmes as the world's youngest self-made female billionaire and ranked her #110 on the Forbes 400 in 2014. Theranos was valued at $9 billion and had raised more than $400 million in venture capital. By the end of 2014, her name appeared on 18 U.S. patents and 66 foreign patents. During 2015, Holmes established agreements with Cleveland Clinic, Capital Blue Cross, and AmeriHealth Caritas to use Theranos technology.
Downfall
of The Wall Street Journal initiated a secret, months-long investigation of Theranos after he received a tip from a medical expert who thought that Theranos's Edison blood testing device seemed suspicious. Carreyrou spoke to ex-employee whistleblowers and obtained company documents. When Holmes' lawyer David Boies learned of the investigation, Holmes initiated a campaign to stop Carreyrou from publishing, which included legal and financial threats against both the Journal and the whistleblowers tied to the expected release of trade secrets.In October 2015, despite Boies's legal threats and strong-arm tactics, the Journal published Carreyrou's "bombshell article" detailing how the Edison device gave inaccurate results, and revealing that the company had been using commercially available machines manufactured by other companies for most of its testing. Carreyrou continued to report problems with the company and Holmes's conduct in a series of articles and, in 2018, published a book titled Bad Blood: Secrets and Lies in a Silicon Valley Startup, detailing his investigation of Theranos.
Holmes denied all the claims, calling the Journal a "tabloid" and promising the company would publish data on the accuracy of its tests. She appeared on CNBC's Mad Money the same evening the article was published. Jim Cramer said, "The article was pretty brutal", to which Holmes responded, "This is what happens when you work to change things, first they think you're crazy, then they fight you, and then all of a sudden you change the world."
In January 2016, the Centers for Medicare and Medicaid Services sent a warning letter to Theranos after an inspection of its Newark, California, laboratory uncovered irregularities with staff proficiency, procedures, and equipment. CMS regulators proposed a two-year ban on Holmes from owning or operating a certified clinical laboratory after the company had not fixed problems in its California lab in March 2016. On The Today Show, Holmes said she was "devastated we did not catch and fix these issues faster" and said the lab would be rebuilt with help from a new scientific and medical advisory board.
In July 2016, CMS banned Holmes from owning, operating, or directing a blood-testing service for a period of two years. Theranos appealed that decision to a U.S. Department of Health and Human Services appeals board. Shortly thereafter, Walgreens ended its relationship with Theranos and closed its in-store blood collection centers. The U.S. Food and Drug Administration also ordered the company to cease use of its Capillary Tube Nanotainer device, one of its core inventions.
In 2017, the State of Arizona filed suit against Theranos, alleging that the company had sold 1.5 million blood tests to Arizonans while concealing or misrepresenting important facts about those tests. In April 2017, the company settled the lawsuit by agreeing to refund the cost of the tests to consumers, and to pay $225,000 in civil fines and attorney fees, for a total of $4.65 million. Other reported ongoing actions include an unspecified investigation by the U.S. Federal Bureau of Investigation and two class action fraud lawsuits. Holmes denied any wrongdoing.
On May 16, 2017, approximately 99 percent of Theranos shareholders reached an agreement with the company to dismiss all litigation and potential litigation in exchange for shares of preferred stock. Holmes released a portion of her equity to offset any dilution of stock value to non-participating shareholders.
In March 2018, the SEC charged Holmes and Theranos's former president, Ramesh Balwani, with fraud by taking more than $700 million from investors while advertising a false product. The charges of fraud included the company's false claim that its technology was being used by the U.S. Department of Defense in combat situations. The company also lied when it claimed to have a $100-million revenue stream in 2014. That year, the company only made $100,000. On March 14, 2018, Holmes settled the lawsuit. The terms of Holmes's settlement included surrendering voting control of Theranos, returning 18.9 million shares to the company, a ban on holding an officer or director position in a public company for 10 years, and a $500,000 fine.
At its height in 2015, Theranos had more than 800 employees. It dismissed 340 people in October 2016 and an additional 155 in January 2017. In April 2018, Theranos filed a WARN Act notice with the State of California, announcing its plans to permanently lay off 105 employees, leaving it with fewer than two dozen employees. Most of the remaining employees were laid off in August 2018. On September 5, 2018, the company announced that it had begun the process of formally dissolving, with its remaining cash and assets to be distributed to its creditors.